5-Amino-1MQ: Inhibiting NNMT to Prevent Fat Storage and Boost Cellular NAD+
5-Amino-1MQ inhibits NNMT — the enzyme that degrades NAD+ precursors and promotes fat cell differentiation. Mouse data shows fat loss without appetite suppression or CNS stimulation. The mechanism is compelling; human evidence is essentially absent.
Evidence strength
Level 4
Case series / Animal studies
Peer-reviewed refs
2
Reading time
10 min
Key Takeaways
- NNMT (Nicotinamide N-Methyltransferase) degrades NAD+ precursors AND promotes fat storage — inhibiting it simultaneously addresses two independent targets for fat loss and longevity.
- Mouse data showed 5-Amino-1MQ reduced body weight and fat mass without reducing food intake — a 'passive' fat loss mechanism distinct from stimulants or appetite suppressants.
- No human RCTs exist. NNMT plays complex and incompletely understood roles in cancer biology — individuals with cancer history should avoid this compound until more data is available.
- Tier C rating reflects genuine uncertainty, not a minor caveat. This is a promising mechanism with minimal human safety data.
The NNMT Problem You've Never Heard Of
In the complex ecosystem of metabolic enzymes, NNMT (Nicotinamide N-Methyltransferase) is one of the least discussed but most metabolically consequential. It does two problematic things simultaneously:
It degrades NAD+ precursors: NNMT methylates nicotinamide (NAM) — a key NAD+ precursor — converting it to 1-methylnicotinamide for excretion. Higher NNMT activity means less NAM available for NAD+ synthesis. This is why NMN supplementation alone is insufficient if NNMT activity is high — you are filling a leaky bucket.
It promotes fat storage: NNMT is highly expressed in white adipose tissue, and its expression is increased in the fat and liver of obese and diabetic mice. Because NNMT consumes SAM, the body's main methyl donor, it shifts histone methylation in adipose tissue. In mice, knocking NNMT down in fat and liver raised SAM and NAD+ levels, increased energy expenditure and protected against diet-induced obesity.
[2]5-Amino-1MQ inhibits NNMT — addressing both problems simultaneously.
The Mouse Data
A 2018 Biochemical Pharmacology study treated diet-induced obese mice with a potent, selective methylquinolinium NNMT inhibitor from the series that includes 5-Amino-1MQ.
[1] Results:
- Significant reduction in body weight and white fat mass compared to vehicle-treated controls
- No reduction in food intake — weight loss was not due to appetite suppression
- Reduced adipocyte size — existing fat cells shrank
- Lower plasma total cholesterol
- Higher intracellular NAD+ and SAM in fat cells treated with the inhibitors, with suppressed lipogenesis
The finding that fat loss occurred without appetite reduction is mechanistically important: it suggests a passive metabolic shift — the body burns more fat as fuel without the animal eating less. This is the desirable fat loss mechanism: preserve lean mass, preferentially mobilise fat, without the neurological side effects of appetite suppressants.
The Dual NAD+ Mechanism
The combination of 5-Amino-1MQ + NMN creates a comprehensive NAD+ restoration strategy:
5-Amino-1MQ (reduce NAD+ degradation):
- Inhibit NNMT → spare nicotinamide → more substrate for NAD+ synthesis
- Less methyl group consumption from NAM methylation → preserve SAM for other methylation reactions
NMN (increase NAD+ synthesis):
- Directly provide NAD+ precursor that bypasses NAMPT rate-limiting step
- Elevate whole-body NAD+ levels independently of salvage pathway efficiency
The combination is analogous to simultaneously plugging a drain and increasing inflow. Single intervention alone is less effective than addressing both sides of the NAD+ balance.
The NNMT-Cancer Complexity
NNMT is overexpressed in multiple cancers — lung, colorectal, gastric, thyroid. In the tumour microenvironment, NNMT promotes immunosuppression and may facilitate tumour growth and metastasis. This would suggest that inhibiting NNMT could actually be beneficial in cancer contexts.
However, the biology is complex and context-dependent. In some cancer types, NNMT inhibition may have unpredictable effects on tumour biology. Given this complexity and the absence of human safety data, individuals with any cancer history should avoid 5-Amino-1MQ until substantially more evidence exists.
Practical Protocol
- Dose: 50–100mg twice daily (morning and midday) with food
- Avoid evening dosing — potential stimulatory effects from metabolic upregulation
- Cycle: 8 weeks on, 4 weeks off
- Stack: NMN 500mg + 5-Amino-1MQ 100mg in the morning for comprehensive NAD+ optimization
- Monitor: Lipid panel and liver enzymes at baseline and 8 weeks (NNMT is highly expressed in liver)
Related Substances
Scientific References
- [1]Neelakantan H, Vance V, Wetzel MD, et al.. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice — Biochemical Pharmacology (2018)Oxford 5PMID 29155147
- [2]Kraus D, Yang Q, Kong D, et al.. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity — Nature (2014)Oxford 5PMID 24717514
Follow us on Google Search
Add BiohackingHub as a preferred source to see more of our research in Google results.
Related protocols
Partner with BiohackingHub
Editorial placements, sponsorships, and product features for evidence-minded brands.